Suppr超能文献

条件性SCA1转基因小鼠中多聚谷氨酰胺诱导的神经变性的恢复

Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.

作者信息

Zu Tao, Duvick Lisa A, Kaytor Michael D, Berlinger Michael S, Zoghbi Huda Y, Clark H Brent, Orr Harry T

机构信息

Institute of Human Genetics, University of Minnesota, Minneapolis, Minnesota 55455, USA.

出版信息

J Neurosci. 2004 Oct 6;24(40):8853-61. doi: 10.1523/JNEUROSCI.2978-04.2004.

Abstract

Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant, polyglutamine-induced neurodegenerative disorder that results in loss of motor coordination caused primarily by a disruption of cerebellar Purkinje cell function. In this study, we developed a conditional SCA1 mouse model to examine whether stopping expression of mutant ataxin-1 alters the disease phenotype. After cessation of SCA1[82Q] transgene expression, mutant ataxin-1, including that in nuclear inclusions, was cleared rapidly from Purkinje cells. At an early stage of disease, Purkinje cell pathology and motor dysfunction were completely reversible. After halting SCA1 expression at later stages of disease, only a partial recovery was seen. Interestingly, restoration of the ability to perform a complex motor task, the accelerating Rotarod, correlated with localization of mGluR1alpha to the Purkinje cell-parallel fiber synapse. These results show that the progression of SCA1 pathogenesis is dependent on the continuous expression of mutant ataxin-1. Of note, even at a late stage of disease, Purkinje cells retain at least some ability to repair the damage caused by mutant ataxin-1.

摘要

1型脊髓小脑共济失调(SCA1)是一种常染色体显性、多聚谷氨酰胺诱导的神经退行性疾病,主要由小脑浦肯野细胞功能紊乱导致运动协调能力丧失。在本研究中,我们构建了一种条件性SCA1小鼠模型,以研究停止突变型ataxin-1的表达是否会改变疾病表型。在SCA1[82Q]转基因表达停止后,突变型ataxin-1,包括核内包涵体中的突变型ataxin-1,迅速从小脑浦肯野细胞中清除。在疾病早期,浦肯野细胞病理改变和运动功能障碍是完全可逆的。在疾病后期停止SCA1表达后,仅观察到部分恢复。有趣的是,执行复杂运动任务(加速转棒试验)的能力恢复与代谢型谷氨酸受体1α(mGluR1α)定位到浦肯野细胞-平行纤维突触相关。这些结果表明,SCA1发病机制的进展依赖于突变型ataxin-1的持续表达。值得注意的是,即使在疾病晚期,浦肯野细胞至少仍保留一些修复由突变型ataxin-1造成损伤的能力。

相似文献

1
Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.
J Neurosci. 2004 Oct 6;24(40):8853-61. doi: 10.1523/JNEUROSCI.2978-04.2004.
2
Progress in pathogenesis studies of spinocerebellar ataxia type 1.
Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1079-81. doi: 10.1098/rstb.1999.0462.
4
Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice.
Neuron. 2003 May 8;38(3):375-87. doi: 10.1016/s0896-6273(03)00258-7.
6
Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice.
Hum Mol Genet. 2004 Oct 15;13(20):2535-43. doi: 10.1093/hmg/ddh268. Epub 2004 Aug 18.
10
Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability.
J Neurosci. 2015 Aug 12;35(32):11292-307. doi: 10.1523/JNEUROSCI.1357-15.2015.

引用本文的文献

3
Experimental Treatment with Edaravone in a Mouse Model of Spinocerebellar Ataxia 1.
Int J Mol Sci. 2023 Jun 26;24(13):10689. doi: 10.3390/ijms241310689.
4
Therapeutic Strategies for Spinocerebellar Ataxia Type 1.
Biomolecules. 2023 May 2;13(5):788. doi: 10.3390/biom13050788.
5
BDNF is altered in a brain-region specific manner and rescues deficits in Spinocerebellar Ataxia Type 1.
Neurobiol Dis. 2023 Mar;178:106023. doi: 10.1016/j.nbd.2023.106023. Epub 2023 Jan 29.
6
Quantitative proteomic analysis reveals the effects of mu opioid agonists on HT22 cells.
Front Pharmacol. 2023 Jan 9;13:1022449. doi: 10.3389/fphar.2022.1022449. eCollection 2022.
8
Altered brain white matter structural motor network in spinocerebellar ataxia type 3.
Ann Clin Transl Neurol. 2023 Feb;10(2):225-236. doi: 10.1002/acn3.51713. Epub 2022 Dec 8.

本文引用的文献

1
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.
Nat Med. 2004 Aug;10(8):816-20. doi: 10.1038/nm1076. Epub 2004 Jul 4.
2
Desaturase activities in rat model of insulin resistance induced by a sucrose-rich diet.
Lipids. 2003 Jul;38(7):733-42. doi: 10.1007/s11745-003-1121-x.
4
Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice.
Neuron. 2003 May 8;38(3):375-87. doi: 10.1016/s0896-6273(03)00258-7.
5
The ons and offs of inducible transgenic technology: a review.
Neurobiol Dis. 2001 Dec;8(6):923-32. doi: 10.1006/nbdi.2001.0452.
6
Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.
J Neurosci. 2001 Nov 15;21(22):8772-81. doi: 10.1523/JNEUROSCI.21-22-08772.2001.
7
Altered trafficking of membrane proteins in purkinje cells of SCA1 transgenic mice.
Am J Pathol. 2001 Sep;159(3):905-13. doi: 10.1016/S0002-9440(10)61766-X.
10
Impairment of the ubiquitin-proteasome system by protein aggregation.
Science. 2001 May 25;292(5521):1552-5. doi: 10.1126/science.292.5521.1552.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验